RESEARCH · RETATRUTIDE · MOLECULAR DESIGN AND RECEPTOR PHARMACOLOGY
Retatrutide Molecular Design and Receptor Pharmacology: Triagonist Engineering, Potency Balance, Cryo-EM Structures and Unknowns
PurixLab’s Retatrutide 10mg is a research vial of the GIP, GLP-1 and glucagon receptor triple agonist also known as LY3437943. Our earlier articles cover the glucagon receptor, energy expenditure and the liver, single, dual and triple agonist comparisons and pharmacokinetics and half-life. This article steps back to the molecule itself: how it was engineered, what is known about its activity at each receptor, what cryo-EM structures show, and what remains unknown. These are published findings from laboratory, animal and early human research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
From the first triagonists to LY3437943
In 2015, Finan and colleagues reported a monomeric peptide with agonist activity at the GLP-1, GIP and glucagon receptors, with equally aligned activity at each receptor and no cross-reactivity at related receptors. In rodent models it outperformed dual co-agonists and single-receptor agonists on body weight, glucose control and hepatic steatosis. Knockout, pharmacological blockade and chemical knockout experiments indicated that each activity contributed: glucagon to raise energy expenditure, GLP-1 to reduce food intake and improve glucose control, and GIP to strengthen the incretin effect and buffer the glucose-raising effect of glucagon [1].
Several groups then built their own versions. Sanofi’s SAR441255 was based on the exendin-4 sequence, showed balanced activation of all three receptors and, in animal models, did better than a dual GLP-1/glucagon agonist [2]. Novo Nordisk researchers designed triagonists with an “empirically optimized” receptor potency ratio and a protraction strategy suited to weekly use, and reported that these normalised body weight in obese mice. They concluded that glucagon receptor activation was the factor that separated triagonists from mono- and dual agonists [3].
LY3437943 is Eli Lilly’s entry. The discovery paper by Coskun and colleagues in 2022 describes it as a single peptide agonist at the glucagon, GIP and GLP-1 receptors. In vitro, it showed balanced glucagon and GLP-1 receptor activity but more GIP receptor activity. In obese mice it reduced body weight and improved glycaemic control, and the authors attributed the extra weight loss to glucagon-driven energy expenditure on top of the reduced calorie intake driven by GIP and GLP-1 receptor activity [4]. Unlike Finan’s “equally aligned” design, retatrutide is not equal at all three receptors.
The peptide backbone and lipidation
A 2026 review describes retatrutide as a lipidated 39-residue peptide [5]. The cryo-EM study discussed below compares its sequence with the natural hormones and with other multi-agonists. It notes that retatrutide was developed from the GIP backbone, whereas an earlier triagonist, peptide 20, was built on the glucagon backbone [6,7]. Like semaglutide and tirzepatide, it carries a fatty diacid attached through a linker to a lysine side chain, and its sequence includes non-standard amino acids such as α-aminoisobutyric acid and α-methyl-L-leucine [6].
Synthesis has relied mainly on solid-phase methods, which have limits in efficiency, scalability and structural flexibility. A 2026 paper described a hydrophobic tag-assisted liquid-phase route as an alternative [8]. The 2026 review lists scalable synthesis, impurity and potency control, formulation stability and immunogenicity among the pharmaceutical development priorities that are still open [5].
What the cryo-EM structures show
Li and colleagues determined cryo-EM structures of retatrutide bound to each of the three receptors in complex with the Gs protein, published as a 2024 letter in Cell Discovery. In all three, the peptide forms a single continuous helix. Its N-terminal segment reaches into the core of the receptor’s transmembrane domain, and its C-terminal segment contacts the receptor’s extracellular domain. Triple agonism appeared to depend on two things. The peptide keeps common contacts with conserved receptor residues, and it adapts to receptor-specific residues, mainly in the upper part of the binding pocket and at the first extracellular loop. That loop forms a rigid short helix in the GLP-1 and glucagon receptors but is flexible in the GIP receptor. Alanine-substitution experiments measuring cAMP supported the key contacts [6]. The same group had earlier solved structures of tirzepatide and of peptide 20 bound to these receptors, which provide the comparison points [7].
Potency balance, species and signalling
The discovery paper’s abstract describes the profile only qualitatively (more GIP receptor activity, balanced glucagon and GLP-1 receptor activity) [4]. The detailed potency tables at human versus mouse receptors appear in full texts, not in the abstracts we verified. For that reason we do not reproduce specific values here. Species matters because most efficacy data come from rodents. A 2026 study comparing retatrutide with a GIP/glucagon co-agonist, BWB3054, used mouse receptors: BWB3054 was comparably potent to retatrutide at the mouse GIP receptor, 4-fold less potent at the mouse glucagon receptor and more than 100-fold less potent at the mouse GLP-1 receptor [9]. In the same study, retatrutide normalised body weight in obese mice lacking a functional GLP-1 receptor [9].
Signalling beyond cAMP is less well mapped. For tirzepatide, researchers at Lilly and collaborating universities showed bias at the GLP-1 receptor towards cAMP over β-arrestin recruitment, and greater engagement of the GIP receptor than the GLP-1 receptor [10]. Comparable bias data for retatrutide were not found in the abstracts we reviewed. A group in China designing its own triagonists reported biased agonism at the GIP and glucagon receptors and similar metabolic efficacy to retatrutide despite much weaker GIP receptor potency. It suggested that strong activation of all three receptors may not be necessary [11]. In mouse islets, a different triagonist, IUB447, enhanced insulin secretion mainly through the GLP-1 receptor and a Gαq-TRPM5 pathway [12]. Whether retatrutide shares this mechanism has not been shown.
Receptor activity in heart tissue
Two isolated-tissue studies looked at the heart. In mouse atria, retatrutide (100 nM) did not increase force of contraction in left atrial preparations [13]. It did increase beating rate in right atrial preparations, an effect blocked by a glucagon receptor antagonist and attenuated by a protein kinase A inhibitor [13]. In human right atrial tissue obtained during heart surgery, retatrutide from 10 nM up to 100 nM increased force of contraction [14]. Antagonists at each of the three receptors reduced this effect, while a β-blocker did not [14]. The authors attribute both effects to cAMP signalling.
Critical view and unknowns
- Abstract-level potency data are qualitative. Publicly verifiable abstracts describe the receptor balance in words, not numbers, and human versus mouse potency comparisons have to be read from full texts and supplementary tables [4].
- Mechanism in animals is not settled. The discovery work credits glucagon-driven energy expenditure [4]. Yet in one diet-induced obese MASH mouse model, retatrutide reduced body weight by 31% while energy expenditure was not significantly altered [15]. In those mice, fat and lean mass both fell, and hamster liver triglyceride content fell by 50% without a change in histopathology scores [15].
- Structures are snapshots. Cryo-EM complexes with Gs do not capture β-arrestin recruitment, receptor internalisation or tissue-specific signalling [6].
- Species translation. Mouse and human atrial tissue gave different contractile responses, a caution for any rodent-to-human extrapolation [13,14].
- Optimal ratio unknown. Triagonists with very different potency ratios have shown similar efficacy in animals, so it is unclear whether retatrutide’s particular balance is optimal or simply one workable solution [11,3].
- Manufacturing and quality. Impurity and potency control, formulation stability and immunogenicity remain development questions for a long, modified, lipidated peptide [5,8].
In short, the molecular literature on retatrutide is thinner than its clinical profile suggests. There is one discovery paper, one structural letter, and a small number of independent pharmacology studies. Where the retatrutide-specific record was silent, this article broadened to related triagonists, and those findings should not be assumed to transfer.
Retatrutide 10mg at PurixLab
Retatrutide 10mg: a labelled lyophilized research vial with 10mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/retatrutide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36. PubMed 25485909 · doi:10.1038/nm.3761
- Bossart M, Wagner M, Elvert R, et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metab. 2022;34(1):59-74.e10. PubMed 34932984 · doi:10.1016/j.cmet.2021.12.005
- Knerr PJ, Mowery SA, Douros JD, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533. PubMed 35809773 · PMC9305623 · doi:10.1016/j.molmet.2022.101533
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed 35985340 · doi:10.1016/j.cmet.2022.07.013
- Mateescu DM, Capraru ID, Enache B, et al. Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence. Pharmaceutics. 2026;18(10):1277. PubMed 42942810 · PMC13708278 · doi:10.3390/pharmaceutics18101277
- Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024;10(1):77. PubMed 39019866 · PMC11255275 · doi:10.1038/s41421-024-00700-0
- Zhao F, Zhou Q, Cong Z, et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat Commun. 2022;13(1):1057. PubMed 35217653 · PMC8881610 · doi:10.1038/s41467-022-28683-0
- Mao CY, Pang ZJ, Qiao GY, et al. A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide. Org Lett. 2026;28(23):7486-7490. PubMed 42224238 · doi:10.1021/acs.orglett.6c02001
- Perez-Tilve D, Zhang F, Zhang Y, et al. GIPR:GCGR co-agonism restores normal weight in obese rodents. Mol Metab. 2026;108:102365. PubMed 41997446 · PMC13141540 · doi:10.1016/j.molmet.2026.102365
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):140532. PubMed 32730231 · PMC7526454 · doi:10.1172/jci.insight.140532
- Wang S, Liu Y, Yan Z, et al. Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects. J Med Chem. 2025;68(19):20765-20788. PubMed 40958513 · doi:10.1021/acs.jmedchem.5c02032
- Schreier PCF, Beyerle P, Boulassel S, et al. GLP-1/GIP/GCG receptor triagonist (IUB447) enhances insulin secretion via GLP-1 receptor and Gαq signalling pathway in mice. Diabetologia. 2025;68(11):2567-2580. PubMed 40924112 · PMC12534261 · doi:10.1007/s00125-025-06525-0
- Neumann J, Ahlrep U, Hofmann B, et al. Contractile effects of retatrutide in isolated mouse atrial preparations. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(12):17147-17160. PubMed 40464942 · PMC12678479 · doi:10.1007/s00210-025-04335-0
- Neumann J, Ahlrep U, Hofmann B, et al. Inotropic effects of retatrutide in isolated human atrial preparations. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(1):317-327. PubMed 40613938 · PMC12894140 · doi:10.1007/s00210-025-04421-3
- Briand F, Le Cudennec C, Grasset E, et al. Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. Obesity (Silver Spring). 2026;34 Suppl 1(Suppl 1):43-53. PubMed 41741376 · PMC13250738 · doi:10.1002/oby.70155